(Q53510568)

English

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

scientific article published in August 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). (English)

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

0 references

1 reference

based on heuristic

inferred from title

author name string

Carrière P

1

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

Bonhomme D

2

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

Lempérière T

3

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

language of work or name

0 references

publication date

1 August 2000

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

European Psychiatry

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

15

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

321-329

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

5

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dosage of haloperidol for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Functional Status Questionnaire: reliability and validity when used in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2800%2900401-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0924-9338(00)00401-6

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/11032464

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53510568&oldid=1531342930"